Pain Relief Patches Market

Market Study on Pain Relief Patches: North America Leading Regional Market with over One-third Share

Pain Relief Patches Market by Product (Non-steroidal Anti-inflammatory Drug Patches, Opioid Patches and Local Anesthetic Patches)

Report ID: PMRREP33349

Number of Pages: 250

Format: PPT*, PDF, EXCEL

Industry: Healthcare

Published Date: February-2023

Report Price


Buy Now

Market Size (2024 to 2032)

The Global Pain Relief Patches Market is valued at US$ 1.2 billion in 2024 and is estimated to reach US$ 1.9 billion by 2032, expanding at a CAGR of 4.9%. According to this new study by Persistence Market Research, non-steroidal anti-inflammatory drug patches account for a leading market share of 39.5%.

  • Pain relief patches accounted for 15% share of the global transdermal patches market in 2021.

A combination of pharmaceutical sciences and nanotechnology has been a meaningful step toward creating more effective chronic pain medications with fewer side effects. The incorporation of nanotechnology has boosted the sales of pain relief patches, resulting in the authorization of several nanomaterials for medicinal use.

  • To evaluate patients experiencing different levels of pain and their perceptions of pain management and associated symptoms, a patented, non-invasive, and non-drug topical Kailo pain patches was utilized in nanotechnology research.
  • According to a report in the Anesthesia & Pain Research journal, in December 2020, the use of the Kailo pain patch resulted in a 71% reduction in the mean Brief Pain Inventory (BPI) severity, indicating a decrease in pain severity that interferes with daily functioning. Furthermore, 97% of patients reported a reduction in BPI severity when using the Kailo pain patch.
Report Attributes Details
Pain Relief Patches Market Size (2023) US$ 1.1 Billion
Estimated Market Value (2024) US$ 1.2 Billion
Forecasted Market Value (2032) US$ 1.9 Billion
Global Market Growth Rate (2024 to 2032) 4.9% CAGR
Market Share of Top 5 Countries 54.2%
Sample Report

Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get Report Sample

Sales Analysis of Pain Relief Patches (2017 to 2023) Vs. Market Outlook (2024 to 2032)

  • Sales of pain relief patches increased at a CAGR of 4.3% from 2017 to 2021 owing to the growing demand for non-steroidal anti-inflammatory drug patches for chronic pain management.

One of the major factors for the growing demand for pain relief patches is the increasing prevalence of osteoarthritis, diabetic neuropathy, joint injuries, obesity, and disorders caused by hereditary factors. The increasing incidence of metabolic disorders is driving demand for non-opioid pain management treatment patches.

  • According to a collaborative study by the Osteoarthritis Action Alliance (OAAA) and the Centers for Disease Control and Prevention, 1 in every 4 Americans, or 54.4 million people, will have arthritis in 2022, with the number expected to rise to 78 million by 2040. While there are over a hundred different forms of arthritis, osteoarthritis affects 32.5 million people in the United States.

Owing to the rising prevalence of osteoarthritis and growing demand for transdermal patches for treating bone disorders, the market is expected to increase steadily over the coming years.

  • Worldwide demand for pain relief patches is anticipated to increase at a CAGR of 4.9% from 2024 to 2032.
Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How are Manufacturers of Pain Relief Patches Market Strategizing?

The increasing prevalence of cancer is expected to drive the demand for pain relief patches. Chronic pain is a common side effect of cancer treatments and, if left untreated, can significantly impact survivors’ quality of life. To prevent premature such comorbid conditions and side effects such as psychological issues and fatigue, lifestyle changes are recommended. Insufficient stress response can cause dysregulation in the autonomic, endocrine, and inflammatory processes of the body.

Over the coming years, transdermal patches are expected to be an effective treatment option for chronic pain. This presents an opportunity for pain relief patch manufacturers to develop and launch technologically advanced devices to enhance treatment efficacy.

National initiatives have recently been released to promote effective and safe pain management options. Topical formulations offer significant advantages over other delivery methods, as they avoid gastrointestinal absorption and deliver effective concentrations directly to targeted tissues.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

What is Restraining the Demand Growth for Pain Relief Patches?

Lack of awareness among the general population poses a hindrance to the widespread adoption of pain relief patches.

While pain relief patches and transdermal patches offer an effective method of delivering medication through the skin, some individuals may develop an allergic reaction to the adhesive glue used in these products. This can lead to contact dermatitis, a skin condition that causes blisters, rash, and flaking.

Latex, which is commonly used in the production of pain relief patches, can trigger an allergic reaction in some people. This limits the options available to them and consequently restricts the sales of pain relief patches.

Country-wise Insights

Why is the United States a Lucrative Market for Manufacturers of Pain Relief Patches?

  • The United States accounted for 91.5% share of the North American market in 2021.

Increasing prevalence of car accidents, traumatic injuries, and chronic illnesses such as heart attacks and blood clotting is boosting demand for pain relief patches in the United States.

  • The US FDA's approval of a transdermal administration method for asenapine (sold under the brand name SECUADO) for treating schizophrenia in the United States in October 2019 has led to increased demand for pain relief patches for neurological disorders.

How is Demand for Pain Relief Patches Evolving in the United Kingdom?

  • The United Kingdom occupied 16.9% share of the European pain relief patches market in 2021.

The increasing use of opioids for treating pain related to trauma, injury, and severe and chronic illnesses, as well as post-surgical pain is driving the demand for pain relief patches in this country.

  • According to a nationwide observational cohort study in 2021, in England and Wales, a total of 3.1 million surgeries were performed, consisting of 763,730 emergency surgical procedures and 2.34 million elective surgical procedures.

Which Factors are Driving the Demand for Pain Relief Patches in China?

  • China accounted for 45.2% share of the East Asian market in 2021.
  • Sales of patches for pain relief in the country are expected to progress at a CAGR of 3.8% through 2032.
  • The Chinese Center for Disease Control and Prevention and the Chinese Society of Osteoporosis and Bone Mineral Research recently entered into a collaboration to spread awareness regarding musculoskeletal disorders and implement more practical measures.

Category-wise Insights

Which Type of Pain Relief Patch is in High Demand Worldwide?

  • Non-steroidal anti-inflammatory drug patches held a leading market share of 39.5% in 2021 and their sales are expected to advance at a CAGR of 4.1% through 2032.
  • In the journal article titled 'Capsaicin 8% Patch and Chronic Postsurgical Neuropathic Pain', published in September 2021, it was noted that the capsaicin 8% patch (Qutenza), which has been approved by the European Union, is licensed to treat peripheral neuropathic pain (PNP) in adults.

For Which Medical Indication is Pain Relief Patches Generating Significant Sales?

  • Based on medical indication, menstrual cramps accounted for 26.5% share of the global market in 2021.

Changes in lifestyle and dietary choices and environmental factors have had a significant impact on the female body. Dysmenorrhea, or painful periods, is a major cause of pelvic discomfort among women.

Pain Relief Patches Market Competitive Landscape

Due to the presence of many local and major players, the global market for pain relief patches is highly fragmented. In response to competition from local players, major market players are strengthening their distribution channels to expand their reach to a larger customer base. Additionally, manufacturers are developing pain relief patches with improved material compositions to enhance ease of use.

  • In January 2021, Radius Health, Inc. and Endo International signed legal agreements for the exclusive registration, marketing, and distribution of loperamide in Canada. These agreements were signed by Endo Ventures Limited, a subsidiary of Endo International. Additionally, Endo International acquired the rights to the abaloparatide transdermal patch (abaloparatide-TD).

Pain Relief Patches Industry Report Scope

Attribute Details
Forecast Period 2024 to 2032
Historical Data Available for 2017 to 2023
Market Analysis US$ Billion for Value
Key Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East & Africa
Key Countries Covered
  • Unites States
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • United Kingdom
  • Germany
  • Italy
  • Russia
  • Spain
  • France
  • Benelux
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Japan
  • China
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC Countries
  • South Africa
Key Market Segments Covered
  • Product Type
  • Indication
  • Distribution Channel
  • Region
Key Companies Profiled
  • Viatris, Inc. (Mylan)
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Hisamitsu Pharmaceutical Co., Inc.
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Nichiban Co., Ltd.
  • Teikoku Seiyaku Co, Ltd.
  • Mentholatum Company
  • Purdue Pharma L.P.
  • West-Ward Pharmaceuticals Corporation
  • Pfizer, Inc
  • Allergan PLC (Actavis)
  • Endo International PLC
  • Mylan N.V.
  • Corium, Inc.
  • Agile Therapeutics Inc.
Pricing Available upon Request

Pain Relief Patches Industry Research Segmentation

By Product Type:

  • Non-steroidal Anti-inflammatory Drug Patches
    • Ketoprofen Patches
    • Diclofenac Patches
    • Flurbiprofen Patches
    • Piroxicam Patches
  • Opioid Patches
    • Fentanyl Patches
    • Buprenorphine Patches
  • Local Anesthetic Patches
    • Nitroglycerine Patches
    • Capsaicin Patches
    • Lidocaine Patches

By Indication:

  • Menstrual Cramps
  • Orthopedic Pain
  • Neuropathic Pain
  • Post-operative Pain
  • Cardiovascular Pain
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

For report customisation and delivery information contact our sales representative.

Companies Covered in This Report

  • Viatris, Inc. (Mylan)
  • Obalon Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Hisamitsu Pharmaceutical Co., Inc.
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Nichiban Co., Ltd.
  • Teikoku Seiyaku Co, Ltd.
  • Mentholatum Company.
  • Purdue Pharma L.P.
  • West-Ward Pharmaceuticals Corporation
  • Pfizer, Inc
  • Allergan Plc (Actavis)
  • Endo International plc,
  • Mylan N.V..Viatris, Inc. (Mylan

Frequently Asked Questions

The global pain relief patches market is valued at US$ 1.1 billion in 2021 and is set to expand 1.6X by 2032.

Sales of pain relief patches are expected to reach USS$ 1.9 billion by 2032.

Rising prevalence of osteoarthritis and nerve pain is boosting the demand for pain relief patches.

The U.S., the U.K., Germany, China, and Japan are generating high demand for pain relief patches.

North America is one of the key markets for pain relief patches, with the U.S. accounting for 91.5% share of the North American market.

Sales of pain relief patches in Europe are expected to increase at a CAGR of 4.4% through 2032.

The United States, the United Kingdom, Germany, Japan, and China are leading producers of pain relief patches.

Viatris, Teva Pharmaceutical Industries, and Sanofi are key producers of pain relief patches.

Demand for pain relief patches in Latin America is expected to increase at a CAGR of 3.6% through 2032.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate